Latest Clinical & Research News
Advances in cancer therapies have allowed clinicians to better manage cancer and extend the lives of patients, but many therapies can produce serious cardiovascular side effects, from arrhythmias and hypertension, to cardiomyopathy and even heart failure.
Uterine fibroids are highly prevalent in women over 35. As more women delay childbearing, techniques to remove uterine fibroids (leiomyomas) while also preserving fertility are of increasing importance.
Stage II non-small cell lung cancer (NSCLC) represents less than 10 percent of the approximately 234,000 cases of lung cancer diagnosed each year in the United States. Due to its relatively low incidence, not many papers have been published on stage II NSCLC. Furthermore, few clinicians have extensive experience treating it.
The Lung Center at Brigham and Women’s Hospital hosts the largest, and one of only two, lung transplant programs in New England. Through its use of extracorporeal membrane oxygenation (ECMO), the center is improving the outlook for patients with end-stage lung disease who otherwise would be considered too sick for transplant.
About 24.7 million Americans live with asthma, according to the Centers for Disease Control and Prevention. Patients with severe asthma comprise 10 to 15 percent of this figure, said pulmonologist Elliot Israel, MD, co-director of the Severe Asthma Program at Brigham and Women’s Hospital. And yet, he added, caring for this segment of asthma patients accounts for over half the cost of asthma care.
Although surgery and radiation provide good disease control for localized prostate cancer, developing long-lasting approaches for treating metastatic disease has been challenging because resistance to androgen deprivation therapy (ADT) frequently develops.
Members of the Brigham and Women’s Hospital community celebrated in October upon learning that William G. Kaelin Jr., MD, a senior physician-scientist at the Brigham, had won the 2019 Nobel Prize in Physiology or Medicine.
This November, leading experts in cardiology from Brigham and Women’s Hospital presented new findings and cutting-edge research at the American Heart Association’s (AHA) Scientific Sessions 2019 in Philadelphia.
Beginning with methotrexate in the mid-1980s, clinical investigators at Brigham and Women’s Hospital have led the development of a number of drugs for treating rheumatoid arthritis (RA). Thanks to methotrexate and additional progress in the decades since it was approved, the majority of people with RA now experience effective disease management.
There are many challenges to treating autoimmune diseases such as rheumatoid arthritis and lupus. Brigham and Women’s Hospital has recently undertaken a number of new initiatives to address some of these challenges and improve patient care.